Dr. Reddy’s Gets DCGI Nod for Use of Zytorvi in Esophageal Cancer

Dr Reddy's gets DCGI nod for esophageal cancer drug Zytorvi

New Delhi: Dr Reddy’s Laboratories on Wednesday, October 21, said it has received approval from the Drugs Controller General of India (DCGI) for Zytorvi (toripalimab), through which it aims to expand access to first-line immunotherapy for patients with advanced esophageal squamous cell carcinoma (ESCC) in India. The drug has been approved in combination with cisplatin … Get the latest updates in Hyderabad City News, Technology, Entertainment, Sp…

Dr. Reddy’s gets DCGI nod for use of Zytorvi in esophageal cancer

It is the second approved indication in India and expands use of the Shanghai Junshi Biosciences’ drug beyond the initially approved indication in nasopharyngeal carcinoma

Dr Reddy’s gets DCGI’s nod for Zytorvi

The approval is for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC)

Dr Reddy’s Gets DCGI Approval for Zytorvi Cancer Drug, Shares Slip

Shares of Dr Reddy’s Laboratories opened green but failed to keep the momentum and lost all its early gains on 21 October despite the company announcing that it has received approval from the Drugs Controller General of India (DCGI) for Zytorvi, its immunotherapy drug, to treat advanced oesophageal squamous cell...

Dr. Reddy’s gets CDSCO approval for Zytorvi in advanced esophageal cancer

Toripalimab in combination with cisplatin and paclitaxel is approved for first-line treatment of adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma